Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Merck is a global research-driven pharmaceutical company founded in Germany in 1668 and established in the US in 1891. It is committed to helping patients access medicines for chronic conditions through programs that provide free medicines and prescription discounts. Merck contributes to relief efforts such as donating medicines after disasters. It develops drugs through processes of discovery, testing, clinical trials, and regulatory approval. While the pharmaceutical industry faces risks such as lawsuits and loss of patents, Merck diversifies and innovates its portfolio. It competes with large pharmaceutical companies through strategies like job cuts following its merger with Schering-Plough and developing biotech medications.
Merck & co., inc. barclays final 3-10-2015Marcel Brussee
What does Merck's $10B buyback plan say about pharma M&A?
Adding $10 billion to its stock buyback program might mean Merck & Co. ($MRK) wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But The Wall Street Journal sees a different possibility--one the rest of the industry might want to pay attention to.
Source: http://www.fiercepharma.com/story/what-does-mercks-10b-buyback-plan-say-about-pharma-ma/2015-03-26?utm_campaign=SocialMedia
Weekly News Wrap-Uup on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
This document provides an overview of Merck and its recalled drug Vioxx. It discusses Merck's history, leadership, stakeholders, vision, relationship with the FDA, political contributions, use of the blockbuster drug model, direct-to-consumer advertising, Vioxx's rise to fame, emerging safety concerns, and ultimate recall from the market in 2004. The recall came after studies showed Vioxx significantly increased heart attack risks. Questions remain about whether further action should have been taken against those responsible for the deaths and damages caused to consumers by Vioxx.
Merck is facing losing patents on some major drugs like Vasotac and Mevacor. Possible solutions are mergers or focusing on innovation. Merck's new product process was previously slow to respond to competitors, but it now develops cross-functional teams early in the process. Developing specialized patented drugs helps Merck capture new markets. However, drug development faces risks if products fail trials or competitors launch first. The pharmaceutical industry faces challenges like patent expirations and increasing drug resistance. Porter's five forces analysis shows barriers to entry are high in pharmaceuticals due to R&D costs and required scale, while buyers have significant bargaining power.
Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Merck is a global research-driven pharmaceutical company founded in Germany in 1668 and established in the US in 1891. It is committed to helping patients access medicines for chronic conditions through programs that provide free medicines and prescription discounts. Merck contributes to relief efforts such as donating medicines after disasters. It develops drugs through processes of discovery, testing, clinical trials, and regulatory approval. While the pharmaceutical industry faces risks such as lawsuits and loss of patents, Merck diversifies and innovates its portfolio. It competes with large pharmaceutical companies through strategies like job cuts following its merger with Schering-Plough and developing biotech medications.
Merck & co., inc. barclays final 3-10-2015Marcel Brussee
What does Merck's $10B buyback plan say about pharma M&A?
Adding $10 billion to its stock buyback program might mean Merck & Co. ($MRK) wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But The Wall Street Journal sees a different possibility--one the rest of the industry might want to pay attention to.
Source: http://www.fiercepharma.com/story/what-does-mercks-10b-buyback-plan-say-about-pharma-ma/2015-03-26?utm_campaign=SocialMedia
Weekly News Wrap-Uup on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
This document provides an overview of Merck and its recalled drug Vioxx. It discusses Merck's history, leadership, stakeholders, vision, relationship with the FDA, political contributions, use of the blockbuster drug model, direct-to-consumer advertising, Vioxx's rise to fame, emerging safety concerns, and ultimate recall from the market in 2004. The recall came after studies showed Vioxx significantly increased heart attack risks. Questions remain about whether further action should have been taken against those responsible for the deaths and damages caused to consumers by Vioxx.
Merck is facing losing patents on some major drugs like Vasotac and Mevacor. Possible solutions are mergers or focusing on innovation. Merck's new product process was previously slow to respond to competitors, but it now develops cross-functional teams early in the process. Developing specialized patented drugs helps Merck capture new markets. However, drug development faces risks if products fail trials or competitors launch first. The pharmaceutical industry faces challenges like patent expirations and increasing drug resistance. Porter's five forces analysis shows barriers to entry are high in pharmaceuticals due to R&D costs and required scale, while buyers have significant bargaining power.
Merck: Global Health and Access to MedicinesTony Sebastian
Merck is a global pharmaceutical company that developed many important drugs and vaccines. It faces issues in pricing policies, patents, and expanding access to medicine in developing countries with poor infrastructure and low incomes. Merck addresses these issues through initiatives like ACHAP in Botswana and Accelerating Access Initiative that provide HIV medicines at discounted prices. It also has a differential pricing policy that sets prices based on a country's development level and disease burden. Merck works to improve access while maintaining incentives for drug innovation through partnerships and tailored pricing strategies.
Global medical technology research and development expenditure is forecast to grow 3.3% annually to $25.3 billion by 2018. Roche will lead the in vitro diagnostics market with $9.9 billion in sales and an 18% market share. Medtronic will remain the number one cardiology company with $10.4 billion in global sales and 21% market share. Johnson & Johnson's acquisition of Synthes will make it the number one player in the orthopedics market with an expected 30% worldwide market share.
Global Research & Data Services is releasing new market analysis reports on in vitro diagnostics markets in 12 countries and globally. The reports provide information on market size, segmentation, trends and forecasts. They analyze the overall in vitro diagnostics market as well as markets for clinical chemistry, genetic testing, hematology and other segments. The reports also include country overviews and business indicators. They can be purchased individually for €490 or as part of a global package.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
The “Global mRNA Vaccines and Therapeutics Market” is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Trends in the pharmaceutical industry include increased use of adaptive trials, focus on orphan drugs, and outsourcing of drug development. Adaptive trials allow sponsors to react to data in real time to improve decision making. As blockbuster drugs lose patent protection, companies are turning to orphan drugs for new products. Growing costs are also driving outsourcing and use of multiple countries for clinical trials to reduce expenses.
Sweden In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genet...ReportsnReports
This document provides a detailed 269-page market report on the in vitro diagnostics market in Sweden from 2004-2018. It includes market segmentation, revenue figures, company shares and distribution shares for various IVD categories such as clinical chemistry, genetic testing, haematology, histology and cytology, immuno chemistry, infectious immunology and microbiology culture. The report also provides profiles of the major players in the Sweden IVD market.
The document summarizes the challenges facing the pharmaceutical industry and Bayer Schering Pharma's strategies to address these challenges. It discusses increasing costs, regulatory hurdles, generics competition, and the need for innovation. It then outlines Bayer Schering Pharma's strategies, which include focusing R&D on four key therapeutic areas, improving efficiency and productivity, and sourcing external innovation. The document provides an overview of Bayer Schering Pharma's pipeline and top selling products.
The document proposes a new model called the Health Impact Fund (HIF) to stimulate research and development of life-saving pharmaceuticals. The HIF would reward drug developers based on the actual health impact of their products, as measured by quality-adjusted life years (QALYs). Developers could opt into the HIF and sell their drugs at low prices in exchange for reward payments over 10 years. The HIF aims to address current inefficiencies in drug development and access by incentivizing research for neglected diseases and making drugs affordable for more people. A pilot program is suggested to test the HIF model.
Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Gene...ReportsnReports
This document provides a summary and analysis of the Austria In Vitro Diagnostics market from 2004-2018. It covers market segmentation and revenue for major categories including clinical chemistry, genetic testing, haematology, histology and cytology, immuno chemistry, infectious immunology, and microbiology culture. It also provides company profiles of major players in the Austria IVD market and details of partnerships, products in development, and other financial deals in the industry.
Denmark Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Multipara...ReportsnReports
This document provides a 173-page report on the Denmark patient monitoring market outlook from 2012 to 2018. It includes market segmentation data, revenue and volume forecasts, average pricing, and company market shares for various patient monitoring product categories including fetal monitors, multiparameter monitors, neonatal monitors, non-invasive blood pressure monitors, and others. Major companies covered in the report include Philips Healthcare, GE Healthcare, and Draegerwerk AG & Co. KGaA. The report is based on proprietary research and is intended to help readers develop business and market strategies for the Denmark patient monitoring industry.
This document discusses patents, generics, and details of specific drugs:
- A patent is a government-issued license granting exclusive rights to an invention for a set period of time, usually preventing others from making, using, or selling the invention.
- When a drug's patent expires, generic companies can file abbreviated new drug applications (ANDAs) to produce generic versions, increasing competition and lowering drug costs.
- The document provides examples of drug patents that have expired and the generic approvals that followed, including details on litigation in some cases.
China IVD Market, Share, Trends, Regulations, Reimbursement & Key Players Ana...iGATE RESEARCH
iGATE Research has released a research report on “China IVD Market, Share, Trends, Regulations, Reimbursement & Key Players Analysis - Forecast to 2025”
Click here to view the complete report: http://igateresearch.com/FullReportDetail.php?p=147
Contact US
iGATE Research PVT LTD
Ravi Sinha
Sales Manager
Marketing and Sales Divison
Email: ravi.sinha@igateresearch.com
Contact: +91-858-684-0791, +91-821-092-7469 (INDIA)
Web: www.igateresearch.com
Pharmaceutical manufacturing health safety 2-aameerkahn
This document discusses occupational health and safety hazards for women working in the pharmaceutical manufacturing industry. It begins by providing background on the industry, noting that while it aims to ensure product safety, less is known about workplace hazards. The industry employs many women, and women face unique biological and ergonomic risks. The document then examines a wide range of chemical, biological, safety, and stress-related hazards in the industry. It reviews approaches to hazard prevention and relevant laws. Finally, it concludes that more research is needed on gender-specific risks and provides recommendations to improve occupational health and safety.
Pharma Leader Series Top 25 Ophthalmic Drug Manufacturers 2015-2025Visiongain
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1404/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2015-2025
Netherlands In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry ...ReportsnReports
This document provides a summary of a report on the in vitro diagnostics market in the Netherlands from 2004-2018. The 275-page report segments the market into clinical chemistry, genetic testing, haematology, histology and cytology, immuno chemistry, infectious immunology, and microbiology culture. It provides revenue and company share data for each segment, and profiles major companies in the Dutch IVD market. The report aims to help readers develop business and market strategies for key segments.
Global Air Quality Monitoring Market PPT: Demand, Trends and Business Opport...IMARC Group
The document summarizes a report about the global air quality monitoring market. It discusses key trends such as rising pollution levels driving demand for air quality monitors. The market is expected to grow to $6.5 billion by 2027 due to stringent regulations and new affordable monitor options. Major players in the industry include Thermo Fisher Scientific, Siemens, and Emerson Electric.
The document provides an overview of the global and Indian pharmaceutical industries. It discusses key metrics like global sales, R&D spending, mergers and acquisitions, and future projections. The global pharmaceutical market experienced slow growth in 2012 due to many blockbuster drug patents expiring, but sales are expected to steadily increase to $895 billion by 2018. The Indian pharmaceutical market is also growing, driven by factors like increasing demand from emerging markets, greater acceptance of medical treatment, and a growing elderly population in India.
Global Veterinary Reference Laboratory (VRL) Market Research, 2018 to 2025Signitech
The global veterinary reference laboratory (VRL) market size was valued at USD 2.350 billion in 2016 and is expected to grow with CAGR of 9.1% during the forecast period.
Greece Anesthesia and Respiratory Devices Investment Opportunities, Analysis ...ReportsnReports
This report provides an in-depth analysis of the anesthesia and respiratory devices market in Greece from 2004-2018. It includes market size and forecasts by device category, along with company market shares. The 220-page report contains detailed data on revenue, volume, and price trends for various device segments like respiratory devices, anesthesia machines, and sleep apnea diagnostic systems. It also profiles the major companies operating in the Greece anesthesia and respiratory devices space.
Weekly News Wrap-up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Weekly News Wrap-up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Merck: Global Health and Access to MedicinesTony Sebastian
Merck is a global pharmaceutical company that developed many important drugs and vaccines. It faces issues in pricing policies, patents, and expanding access to medicine in developing countries with poor infrastructure and low incomes. Merck addresses these issues through initiatives like ACHAP in Botswana and Accelerating Access Initiative that provide HIV medicines at discounted prices. It also has a differential pricing policy that sets prices based on a country's development level and disease burden. Merck works to improve access while maintaining incentives for drug innovation through partnerships and tailored pricing strategies.
Global medical technology research and development expenditure is forecast to grow 3.3% annually to $25.3 billion by 2018. Roche will lead the in vitro diagnostics market with $9.9 billion in sales and an 18% market share. Medtronic will remain the number one cardiology company with $10.4 billion in global sales and 21% market share. Johnson & Johnson's acquisition of Synthes will make it the number one player in the orthopedics market with an expected 30% worldwide market share.
Global Research & Data Services is releasing new market analysis reports on in vitro diagnostics markets in 12 countries and globally. The reports provide information on market size, segmentation, trends and forecasts. They analyze the overall in vitro diagnostics market as well as markets for clinical chemistry, genetic testing, hematology and other segments. The reports also include country overviews and business indicators. They can be purchased individually for €490 or as part of a global package.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
The “Global mRNA Vaccines and Therapeutics Market” is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Trends in the pharmaceutical industry include increased use of adaptive trials, focus on orphan drugs, and outsourcing of drug development. Adaptive trials allow sponsors to react to data in real time to improve decision making. As blockbuster drugs lose patent protection, companies are turning to orphan drugs for new products. Growing costs are also driving outsourcing and use of multiple countries for clinical trials to reduce expenses.
Sweden In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genet...ReportsnReports
This document provides a detailed 269-page market report on the in vitro diagnostics market in Sweden from 2004-2018. It includes market segmentation, revenue figures, company shares and distribution shares for various IVD categories such as clinical chemistry, genetic testing, haematology, histology and cytology, immuno chemistry, infectious immunology and microbiology culture. The report also provides profiles of the major players in the Sweden IVD market.
The document summarizes the challenges facing the pharmaceutical industry and Bayer Schering Pharma's strategies to address these challenges. It discusses increasing costs, regulatory hurdles, generics competition, and the need for innovation. It then outlines Bayer Schering Pharma's strategies, which include focusing R&D on four key therapeutic areas, improving efficiency and productivity, and sourcing external innovation. The document provides an overview of Bayer Schering Pharma's pipeline and top selling products.
The document proposes a new model called the Health Impact Fund (HIF) to stimulate research and development of life-saving pharmaceuticals. The HIF would reward drug developers based on the actual health impact of their products, as measured by quality-adjusted life years (QALYs). Developers could opt into the HIF and sell their drugs at low prices in exchange for reward payments over 10 years. The HIF aims to address current inefficiencies in drug development and access by incentivizing research for neglected diseases and making drugs affordable for more people. A pilot program is suggested to test the HIF model.
Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Gene...ReportsnReports
This document provides a summary and analysis of the Austria In Vitro Diagnostics market from 2004-2018. It covers market segmentation and revenue for major categories including clinical chemistry, genetic testing, haematology, histology and cytology, immuno chemistry, infectious immunology, and microbiology culture. It also provides company profiles of major players in the Austria IVD market and details of partnerships, products in development, and other financial deals in the industry.
Denmark Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Multipara...ReportsnReports
This document provides a 173-page report on the Denmark patient monitoring market outlook from 2012 to 2018. It includes market segmentation data, revenue and volume forecasts, average pricing, and company market shares for various patient monitoring product categories including fetal monitors, multiparameter monitors, neonatal monitors, non-invasive blood pressure monitors, and others. Major companies covered in the report include Philips Healthcare, GE Healthcare, and Draegerwerk AG & Co. KGaA. The report is based on proprietary research and is intended to help readers develop business and market strategies for the Denmark patient monitoring industry.
This document discusses patents, generics, and details of specific drugs:
- A patent is a government-issued license granting exclusive rights to an invention for a set period of time, usually preventing others from making, using, or selling the invention.
- When a drug's patent expires, generic companies can file abbreviated new drug applications (ANDAs) to produce generic versions, increasing competition and lowering drug costs.
- The document provides examples of drug patents that have expired and the generic approvals that followed, including details on litigation in some cases.
China IVD Market, Share, Trends, Regulations, Reimbursement & Key Players Ana...iGATE RESEARCH
iGATE Research has released a research report on “China IVD Market, Share, Trends, Regulations, Reimbursement & Key Players Analysis - Forecast to 2025”
Click here to view the complete report: http://igateresearch.com/FullReportDetail.php?p=147
Contact US
iGATE Research PVT LTD
Ravi Sinha
Sales Manager
Marketing and Sales Divison
Email: ravi.sinha@igateresearch.com
Contact: +91-858-684-0791, +91-821-092-7469 (INDIA)
Web: www.igateresearch.com
Pharmaceutical manufacturing health safety 2-aameerkahn
This document discusses occupational health and safety hazards for women working in the pharmaceutical manufacturing industry. It begins by providing background on the industry, noting that while it aims to ensure product safety, less is known about workplace hazards. The industry employs many women, and women face unique biological and ergonomic risks. The document then examines a wide range of chemical, biological, safety, and stress-related hazards in the industry. It reviews approaches to hazard prevention and relevant laws. Finally, it concludes that more research is needed on gender-specific risks and provides recommendations to improve occupational health and safety.
Pharma Leader Series Top 25 Ophthalmic Drug Manufacturers 2015-2025Visiongain
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1404/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2015-2025
Netherlands In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry ...ReportsnReports
This document provides a summary of a report on the in vitro diagnostics market in the Netherlands from 2004-2018. The 275-page report segments the market into clinical chemistry, genetic testing, haematology, histology and cytology, immuno chemistry, infectious immunology, and microbiology culture. It provides revenue and company share data for each segment, and profiles major companies in the Dutch IVD market. The report aims to help readers develop business and market strategies for key segments.
Global Air Quality Monitoring Market PPT: Demand, Trends and Business Opport...IMARC Group
The document summarizes a report about the global air quality monitoring market. It discusses key trends such as rising pollution levels driving demand for air quality monitors. The market is expected to grow to $6.5 billion by 2027 due to stringent regulations and new affordable monitor options. Major players in the industry include Thermo Fisher Scientific, Siemens, and Emerson Electric.
The document provides an overview of the global and Indian pharmaceutical industries. It discusses key metrics like global sales, R&D spending, mergers and acquisitions, and future projections. The global pharmaceutical market experienced slow growth in 2012 due to many blockbuster drug patents expiring, but sales are expected to steadily increase to $895 billion by 2018. The Indian pharmaceutical market is also growing, driven by factors like increasing demand from emerging markets, greater acceptance of medical treatment, and a growing elderly population in India.
Global Veterinary Reference Laboratory (VRL) Market Research, 2018 to 2025Signitech
The global veterinary reference laboratory (VRL) market size was valued at USD 2.350 billion in 2016 and is expected to grow with CAGR of 9.1% during the forecast period.
Greece Anesthesia and Respiratory Devices Investment Opportunities, Analysis ...ReportsnReports
This report provides an in-depth analysis of the anesthesia and respiratory devices market in Greece from 2004-2018. It includes market size and forecasts by device category, along with company market shares. The 220-page report contains detailed data on revenue, volume, and price trends for various device segments like respiratory devices, anesthesia machines, and sleep apnea diagnostic systems. It also profiles the major companies operating in the Greece anesthesia and respiratory devices space.
Weekly News Wrap-up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Weekly News Wrap-up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
This document provides a weekly summary of news and financial market performance in the healthcare industry:
- AstraZeneca sold marketing rights to anesthetics for up to $770 million. Elekta will distribute Koold Medical's brachytherapy applicators in the US. Gerresheimer extended its syringe line.
- Bristol-Myers reported positive phase 2 data for Opdivo. Merck acquired Afferent Pharmaceuticals. Thermo Fisher partnered with Cytonome. UnitedHealth appointed a new CFO.
- Indivior and Orion were top European performers this week. Novo Nordisk and Stada were worst performers. Asia Pacific saw the largest weekly decline at -4.
- Fresenius saw adjusted net income rise 24% in Q1 due to new generic drugs and supply issues at rivals. Fresenius Medical Care confirmed 15-20% net income growth target for the year after Q1 net income rose 9%.
- Grifols' Q1 net revenues increased 5.6% to $1.1 billion, with recurring sales up 7.1%. Novo Nordisk plans to meet all of Russia's insulin demand in coming years.
- Sanofi said it will try to replace Medivation's board if it does not engage in takeover talks. Smith & Nephew reported 3% revenue growth in Q1 and backed full-year guidance.
Advanced Medical Isotope Corporation is developing a brachytherapy device called RadioGel for cancer treatment in humans and animals. It plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. It has the potential to treat multiple cancer types more effectively than existing therapies.
Advanced Medical Isotope Corporation is developing a brachytherapy device called RadioGel for cancer treatment in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval for human use. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel that solidifies inside the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing deals. It is working with national labs and universities to optimize the device and treatment techniques.
The document summarizes perspectives from a panel of finance directors on successful collaborations in the biopharmaceutical industry. The panel emphasizes clear communication, understanding partners' perspectives, resolving disputes internally, and adhering to collaboration agreements while considering real-world flexibility. It also provides examples of specific company collaborations and financial arrangements.
J & J Solutions has developed a closed system transfer device for safer handling of chemotherapy drugs. Their device eliminates risks of contamination, standardizes compounding to reduce errors, improves workflow efficiency, and reduces costs. They are seeking funding to complete product development including alpha and beta testing, obtain FDA approval, and launch the product to address a $1 billion market that is growing due to increasing cancer rates.
- Sanofi's CEO Olivier Brandicourt presented at a healthcare conference on September 14, 2018.
- He discussed Sanofi's continued progress on its strategic transformation including acquiring new assets, driving simplification through restructuring, reshaping its portfolio, and executing new product launches.
- Brandicourt highlighted several potentially significant drug approvals and trial results for new drugs and indications expected over the next 12 months that could further advance Sanofi's growth.
- He concluded that while Sanofi saw impacts from recent drug losses of exclusivity in the first half of 2018, performance was otherwise in line with expectations and several factors position Sanofi for a new growth phase in the second half of
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing, while pursuing FDA approval for human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. Advanced Medical Isotope Corporation ultimately aims to gain FDA approval to treat cancers like skin cancer and liver cancer in humans using its RadioGel platform.
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing, while pursuing FDA approval for human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. Advanced Medical Isotope Corporation ultimately aims to gain FDA approval to treat cancers like skin cancer and liver cancer in humans using its RadioGel platform.
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing. It is working towards FDA approval for human cancer indications like skin cancer. RadioGel consists of radioactive yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. It is led by an experienced management team and advises by world-class medical and scientific boards.
Celldex reported that its phase III ACT IV trial of Rintega for glioblastoma was stopped early after a recommendation from the data safety monitoring board. The control arm performed just as well as the Rintega arm, with a median overall survival of 20.4 months for Rintega patients and 21.1 months for control patients. Celldex shares fell over 50% on the news. Company executives said they are analyzing the data to understand why the control arm performed so well but currently have no explanation. Celldex has five other active programs and sufficient cash to fund operations through 2017. Its next program to report data is varlilumab, an anti-CD27 antibody.
The Alliance for Regenerative Medicine (ARM) is the leading global advocate for regenerative and advanced therapies. It fosters research, development, investment, and commercialization of transformative treatments and cures. ARM leverages the expertise of its members to promote legislative, regulatory, and public support for this expanding field of medicine.
Sanofi reported its Q2 2018 results. Key highlights include:
- Q2 sales were €8.2 billion, up 1.5% at constant exchange rates. Business EPS was €1.25.
- Strong growth in Specialty Care, driven by immunology and rare blood disorders, largely offset declines from US generics losses of exclusivity and vaccines phasing.
- Dupixent and Kevzara sales grew significantly in immunology. Rare blood disorder franchise contributed €257 million following acquisition.
- Vaccines sales declined 15.7% due to difficult prior year comparables and phasing in emerging markets.
- Consumer Healthcare grew 4.1% led by emerging markets. Diabetes sales
Regenerative Medicine Industry Outlook 2014Pete Shuster
The document summarizes the regenerative medicine field based on a report from the Alliance for Regenerative Medicine, including an overview of major industry players and subsectors, clinical trials and products in development, financial performance and investments in 2013, and insights from a panel discussion on key areas of focus. It analyzes trends in cell and gene therapies, areas attracting pharmaceutical investment, and challenges facing the commercialization of regenerative medicine technologies and therapies.
This document brings together a set
of latest data points and publicly
available information relevant for
Healthcare Industry. We are very
excited to share this content and
believe that readers will benefit from
this periodic publication immensely.
Vivos Inc. is developing RadioGel, a next-generation radiopharmaceutical device to treat cancer. The company plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval for multiple human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies at body temperature. Vivos expects to begin sales to private veterinary clinics in 2018 and obtain international licensing revenue. The company is led by an experienced management team and advised by world-class medical and scientific boards regarding FDA approval and expanding RadioGel's applications to additional cancer types.
Similar to Weekly Health Care News (2016-06-04) (20)
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...rightmanforbloodline
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)bkling
Your mindset is the way you make sense of the world around you. This lens influences the way you think, the way you feel, and how you might behave in certain situations. Let's talk about mindset myths that can get us into trouble and ways to cultivate a mindset to support your cancer survivorship in authentic ways. Let’s Talk About It!
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdfDr Rachana Gujar
The "Comprehensive Rainy Season Advisory: Safety and Preparedness Tips" offers essential guidance for navigating rainy weather conditions. It covers strategies for staying safe during storms, flood prevention measures, and advice on preparing for inclement weather. This advisory aims to ensure individuals are equipped with the knowledge and resources to handle the challenges of the rainy season effectively, emphasizing safety, preparedness, and resilience.
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
1. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page1
Focus on Europe
Focus on North America
Focus on Asia Pacific
AstraZeneca announced positive data from a phase III study (FALCON) on its breast cancer drug,
Faslodex (fulvestrant/500mg). (finance.yahoo.com)
Elekta’s Leksell Ga a K ife Icon, a precise and sophisticated system for radiosurgery treatment,
has been cleared for clinical use by Japanese and U.S. authorities. (businesswire.com)
Fresenius Medical Care has established a subsidiary focusing on regenerative medicine. Unicyte AG
will pursue research into kidney and liver diseases, diabetes and cancer. (nephrologynews.com)
Novartis opened its third global facility with a $1 billion research and development campus and a
capacity of 1’300 employees in Shanghai. (ibtimes.com)
Qiagen launched its liquid biopsy workflow for clinical cancer research using its GeneReader NGS
System for next-generation sequencing. Illumina filed for patent infringement. (prnewswire.com)
Roche’s subcutaneous formulation of MabThera (rituximab) has been approved by the EC for the
treatment of patients suffering from relapsed/refractory CLL. (finance.yahoo.com)
Weekly News Wrap-Up: HEALTH CARE Industry
No. 14
2016-06-04
AstraZeneca Biogen Chugai Daiichi Sankyo Elekta Fresenius Medical Care
Gilead Sciences Kaken Medtronic Novartis Qiagen Roche Valeant Vertex
SPOTLIGHT
COMPANY NEWS
Biogen and AbbVie have won approval from the FDA for their new multiple sclerosis drug, Zinbryta
(daclizumab), that can be used at home and only requires one injection a month. (fiercebiotech.com)
Gilead Sciences gained a positive opinion for Epclusa, indicated for patients suffering from HCV
infection, from a committee of the European Medicines Agency. (businessfinancenews.com)
Medtronic reported fiscal Q4 earnings of $1.1 billion, compared with a loss of 1 million in the same
period a year ago. Revenue increased to $7.57 billion from $7.30 billion. (marketwatch.com)
Valeant rejected a combined takeover approach from Takeda and private-equity firm TPG. It came
before Valeant hired Joseph Papa as its new CEO. (finance.yahoo.com)
Vertex announced that the FDA has accepted for review a supplemental New Drug Application for
the use of ORKAMBI® (lumacaftor/ivacaftor). (smarteranalyst.com)
Chugai concluded a license agreement with Roche for SA237, an investigational, humanized
monoclonal antibody that targets the IL-6 receptor, created by Chugai. (pharmabiz.com)
Daiichi Sankyo said it will not proceed with the second part of its late-stage study on the lung cancer
drug, patritumab, as it did not meet the required efficacy criteria in the first part. (reuters.com)
Kaken and the Korea-based firm, Dong-A ST, concluded an exclusive distribution agreement for the
topical formulation for Onychomycosis "Clenafin / Jublia" in Korea. (reuters.com)
2. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page2
Regional Comparison
Focus on Europe
98%
99%
100%
101%
102%
2016-05-30 2016-05-31 2016-06-01 2016-06-02 2016-06-03
Europe North America Asia/Pacific
This week’s sto k perfor a e of the world’s iggest listed health are o pa ies shows a negative
development of -0.4% while their one year loss reaches -6.0%. Strongest change occurred in the
European region with -1.2% on a weekly basis and -8.9% on a yearly basis. North America decreased
by -0.3% whereas Asia/ Pacific grew by +0.5%, showing -7.3% and +18.6% for one year respectively.
Weekly News Wrap-Up: HEALTH CARE Industry
No. 14
2016-06-04
Coloplast Elekta Fresenius Medical Care Genmab Hikma
Indivior Stada Swedish Orphan UCB William Demant
SPOTLIGHT
FINANCIAL MARKET NEWS
Taki g a look at Europe’s top perfor er this week, the most striking candidate is Indivior, gaining
+36.6% on a weekly basis while its one year loss reaches -7.9%. Second winner from Europe is
William Demant with a gain of +6.6% this week, while its one year increase amounts to +21.6%.
Regarding the lower end of the weekly performance ranking, Elekta takes the lead due to its decline
of -5.9% compared to its one year growth of +11.4%. Next is Stada, suffering from a decrease of -
4.3% this week and scoring a one year performance of +51.4%.
top 5 companies closing price 1 week change 1 year change 1 week'shigh 1 week'slow 1 year'shigh 1 year'slow
Indivior 2.95 +36.68% -7.92% 3.06 2.16 3.89 1.61
William Demant 18.40 +6.63% +21.65% 19.05 18.40 19.05 3.57
Genmab 167.14 +5.39% +108.48% 167.30 156.77 167.44 67.98
Hikma 29.06 +4.76% +4.06% 29.75 28.28 35.02 21.35
UCB 66.89 +3.53% +0.20% 67.15 64.22 85.56 61.98
flop 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Elekta 6.64 -5.98% +11.46% 7.07 6.61 8.11 5.50
Stada 47.37 -4.34% +51.45% 49.46 46.38 49.46 28.07
Swedish Orphan 11.66 -4.26% -18.04% 12.30 11.65 15.28 9.77
Coloplast 65.48 -3.72% -3.81% 68.24 64.98 78.58 55.69
Fresenius Medical Care 76.25 -2.87% -1.87% 78.85 75.98 83.50 63.11
Index closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
STOXX® Europe 600
Health Care
741.32 -1.21% -8.97% 752.05 736.02 876.66 654.95
STOXX® North America 600
Health Care
834.84 -0.33% -7.36% 851.29 828.41 966.34 730.68
STOXX® Asia/Pacific 600
Health Care
452.48 +0.52% +18.62% 454.18 444.26 454.80 349.32
STOXX® Global 1800
Health Care
737.10 -0.49% -6.09% 749.92 731.94 842.76 647.94